Sign in

CIK 0001737287

  • Non-accelerated filer
  • Smaller reporting company

Allogene Therapeutics, Inc.

Sign in to watch
Ticker
ALLO
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Entity type
Operating
EIN
823562771
Phone
+1 650-457-2700
Business address
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
  1. 4 Other acquisition Director acquired 8,217 shares (other)
  2. 4 Other acquisition President and CEO acquired 18,793 shares (other)
  3. 4 Other disposition Chief Financial Officer disposed of 237,155 shares (other)
  4. 4 Gift Director gave 446,623 shares (gift)
  5. 4 Other acquisition President and CEO acquired 18,793 shares (other)
  6. 4 Other acquisition President and CEO acquired 18,793 shares (other)
  7. 4 Other acquisition Director acquired 8,217 shares (other)
  8. 4 Other acquisition President and CEO acquired 18,793 shares (other)
  9. 4 Other acquisition Director acquired 8,217 shares (other)
  10. 4 Open-market sale Chief Technical Officer sold 48,827 shares at an average $32.11 ($1,567,666)
  11. 4 Other acquisition President and CEO acquired 18,793 shares (other)
  12. 4 Other acquisition Director acquired 8,217 shares (other)
  13. 4 Grant or award EVP of R&D and CMO acquired 105,162 shares (grant or award)
  14. 3 Insider Initial Statement of Ownership
  15. 4 Open-market sale Chief Technical Officer sold 48,827 shares at an average $29.44 ($1,437,603)
  16. 4 Other acquisition Director acquired 8,217 shares (other)
  17. 4 Other acquisition President and CEO acquired 18,793 shares (other)
  18. 4 Other acquisition Director acquired 5,590 shares (other)
  19. 4 Other acquisition President and CEO acquired 16,542 shares (other)
  20. 4 Exercise or conversion Chief Technical Officer acquired 27,816 shares (option exercise)

Page 12 of 14 · 275 filings